Latest News

Fast-food chain Wendy’s (NASDAQ:WEN) met Wall Street’s revenue expectations in Q1 CY2025, but sales fell by 2.1% year on year to $523.5 million. Its non-GAAP profit of $0.20 per share was in line with analysts’ consensus estimates.

Withdrawing funds from a CD early usually comes with a penalty. But in some scenarios, cashing out early makes more financial sense.

Lifting and material handling equipment company Terex (NYSE:TEX) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 4.9% year on year to $1.23 billion. On the other hand, the company’s full-year revenue guidance of $5.4 billion at the midpoint came in 2.2% above analysts’ estimates. Its GAAP profit of $0.31 per share was 29.7% below analysts’ consensus estimates.

A fundamental analysis of (NASDAQ:NICE): Should you consider NICE LTD - SPON ADR (NASDAQ:NICE) for quality investing?

Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) missed Wall Street’s revenue expectations in Q1 CY2025, but sales rose 5.5% year on year to $695.4 million. On the other hand, the company’s full-year revenue guidance of $3.05 billion at the midpoint came in 0.8% above analysts’ estimates. Its non-GAAP profit of $0.21 per share was 43.2% above analysts’ consensus estimates.

SPORTRADAR GROUP AG-A (NASDAQ:SRAD) is a strong growth stock with a bullish technical setup, backed by solid revenue expansion and financial health. Learn why it stands out.

Manufacturing services provider Proto Labs (NYSE:PRLB) reported Q1 CY2025 results exceeding the market’s revenue expectations, but sales fell by 1.3% year on year to $126.2 million. Guidance for next quarter’s revenue was better than expected at $128 million at the midpoint, 1.3% above analysts’ estimates. Its non-GAAP profit of $0.33 per share was 13% above analysts’ consensus estimates.

AMPHENOL CORP-CL A (NYSE:APH) demonstrates strong revenue growth, high ROIC, and solid cash flow—key traits for quality investors. Learn why it stands out in our analysis.

Healthcare services provider BrightSpring Health Services (NASDAQ:BTSG) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with sales up 11.7% year on year to $2.88 billion. The company’s full-year revenue guidance of $12.25 billion at the midpoint came in 2.5% above analysts’ estimates. Its non-GAAP profit of $0.19 per share was significantly above analysts’ consensus estimates.